Advertisement

Topics

Abilify as an Adjunctive Treatment for Refractory Depression.

2014-07-23 21:47:48 | BioPortfolio

Summary

This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing SSRI antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patients’ functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication.

Description

This is a pilot study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing SSRI antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. Fifteen subjects will be given aripiprazole in a flexible dosing schedule and followed for 12 weeks, while continuing their ongoing SSRI medication. Assessments of depressive symptoms, overall functioning, social functioning, and side effects will be completed. It is hypothesized that patients’ functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Depressive Disorder, Major

Intervention

Abilify (aripiprazole)

Location

Mood Disorders Research Program, St. Luke's Roosevelt Hospital
New York
New York
United States
10019

Status

Completed

Source

St. Luke's-Roosevelt Hospital Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:47:48-0400

Clinical Trials [1272 Associated Clinical Trials listed on BioPortfolio]

Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder

The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (abilify) in children with subsyndromal symptoms of bipolar disorder who also have a bipolar ...

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoi...

Aripiprazole in Late Life Bipolar Disorder

The purpose of this research study is to analyze the effectiveness and tolerability of a new medication, aripiprazole (Abilify), in individuals age 50 years and older who have bipolar diso...

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder

Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norep...

PubMed Articles [11873 Associated PubMed Articles listed on BioPortfolio]

The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review.

Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manua...

Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells.

Major depressive disorder (MDD) is a serious debilitating psychiatric disorder. However, the molecular mechanisms of MDD remain largely unknown, and no objective laboratory-based tests are available t...

Norepinephrine Transporter in Major Depressive Disorder: A PET Study.

The norepinephrine transporter has been suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with c...

Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder.

Bifidobacterium and Lactobacillus in the gut have been suggested to have a beneficial effect on stress response and depressive disorder. We examined whether these bacterial counts are reduced in patie...

Role of Janus-Kinases in Major Depressive Disorder.

Major depressive disorder is a severe, common and often chronic disease with a significant mortality due to suicide. The pathogenesis of major depression is still unknown. It is assumed that a reducti...

Medical and Biotech [MESH] Definitions

A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.

An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.

More From BioPortfolio on "Abilify as an Adjunctive Treatment for Refractory Depression."

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Searches Linking to this Trial